In vivo labeling of amyloid with BF-108.

Abstract Detection of aggregated amyloid-beta (Aβ) with a non-invasive imaging modality such as positron emission tomography (PET) was suggested to be ideal for the diagnosis of Alzheimer’s disease (AD) prior to the onset of clinical symptoms. We have been searching for imaging probe candidates with a high affinity for aggregated Aβ in vitro and in vivo and high lipophilicity, a characteristic that allows for the permeation of the blood–brain barrier (BBB). As analyzed by Thioflavin T (ThT) assay and octanol/water partition coefficient test ( P C ), 3-diethylamino-6-(2-fluoroethyl)ethylaminoacridine (BF-108) were found to have high affinity for Aβ aggregates in vitro and high lipophilicity. Intravenously administrated BF-108 labeled Aβ aggregates injected into the amygdala as observed under a fluorescence microscope, showing this compound’s permeability of BBB and an ability to label Aβ in vivo. BF-108 also labeled neuritic senile plaques (SPs), neurofibrillary tangles, and amyloid-laden vessels in temporal and hippocampal sections from AD patients. Following intravenous administration of BF-108 to an APP23 transgenic (TG) mouse, in vivo labeling of endogenous plaques was seen in brain sections by fluorescence microscopy. These properties suggest the potential utility of BF-108 for in vivo imaging of AD pathology.